These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 12176485)

  • 1. Delay of hepatitis C recurrence in liver transplant recipients: impact of mycophenolate mofetil on transplant recipients with severe acute rejection or with renal dysfunction.
    Fasola CG; Netto GJ; Christensen LL; Molmenti EP; Sanchez EQ; Levy MF; Goldstein RM; Klintmalm GB
    Transplant Proc; 2002 Aug; 34(5):1561-2. PubMed ID: 12176485
    [No Abstract]   [Full Text] [Related]  

  • 2. Recurrence of hepatitis C in liver transplant recipients treated with mycophenolate mofetil.
    Fasola CG; Netto GJ; Jennings LW; Christensen LL; Molmenti EP; Sanchez EQ; Levy MF; Goldstein RM; Klintmalm GB
    Transplant Proc; 2002 Aug; 34(5):1563-4. PubMed ID: 12176486
    [No Abstract]   [Full Text] [Related]  

  • 3. A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C.
    Jain A; Kashyap R; Demetris AJ; Eghstesad B; Pokharna R; Fung JJ
    Liver Transpl; 2002 Jan; 8(1):40-6. PubMed ID: 11799484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significance of mycophenolate mofetil treatment in patients with HCV reinfection after liver transplantation: impact on clinical course and histologic damage.
    Bahra M; Neumann UP; Harren M; Jacob D; Langrehr JM; Berg T; Neuhaus R; Neuhaus P
    Transplant Proc; 2002 Nov; 34(7):2934-5. PubMed ID: 12431663
    [No Abstract]   [Full Text] [Related]  

  • 5. A prospective study comparing safety and efficacy of mycophenolate mofetil versus azathioprine in primary liver transplant recipients.
    Fischer L; Sterneck M; Gahlemann CG; Malago M; Rogiers X; Broelsch CE
    Transplant Proc; 2000 Nov; 32(7):2125-7. PubMed ID: 11120098
    [No Abstract]   [Full Text] [Related]  

  • 6. Indication for mycophenolate mofetil therapy in hepatitis C patients undergoing liver transplantation.
    Platz KP; Mueller AR; Willimski C; Mansoorian B; Berg T; Neuhaus R; Hopf U; Radke C; Neuhaus P
    Transplant Proc; 1998 Aug; 30(5):2232-3. PubMed ID: 9723453
    [No Abstract]   [Full Text] [Related]  

  • 7. Indications for mycophenolate mofetil therapy in hepatitis C-patients undergoing liver transplantation.
    Platz KP; Mueller AR; Willimski C; Mansoorian B; Berg T; Neuhaus R; Hopf U; Lobeck H; Neuhaus P
    Transplant Proc; 1998 Jun; 30(4):1468-9. PubMed ID: 9636596
    [No Abstract]   [Full Text] [Related]  

  • 8. Mycophenolate mofetil monotherapy in stable liver transplant recipients with progressive renal failure.
    Detry O; De Roover A; Honoré P; Delwaide J; Jacquet N; Meurisse M
    Transplant Proc; 2002 May; 34(3):782-3. PubMed ID: 12034182
    [No Abstract]   [Full Text] [Related]  

  • 9. Hepatitis C and mycophenolate mofetil--a clarification.
    Fasola CG; Klintmalm GB
    Liver Transpl; 2002 Apr; 8(4):411-2; author reply 412-3. PubMed ID: 11965590
    [No Abstract]   [Full Text] [Related]  

  • 10. Mycophenolate mofetil monotherapy in patients who underwent liver transplantation for hepatitis C cirrhosis.
    Manrique A; Jiménez C; Ortega P; Abradelo M; Gimeno A; Calvo J; Cambra F; -Sterup RL; Morales JM; Moreno E
    Transplant Proc; 2008 Nov; 40(9):2962-4. PubMed ID: 19010160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of mycophenolate mofetil in liver transplant recipients.
    Detry O; de Roover A; Delwaide J; Meurisse M; Honoré P
    Expert Opin Pharmacother; 2003 Nov; 4(11):1949-57. PubMed ID: 14596648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-interleukin-2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation.
    Nelson DR; Soldevila-Pico C; Reed A; Abdelmalek MF; Hemming AW; Van der Werf WJ; Howard R; Davis GL
    Liver Transpl; 2001 Dec; 7(12):1064-70. PubMed ID: 11753908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mycophenolate mofetil rescue therapy in liver transplant recipients: an extended follow-up.
    Gavlik A; Demirbas A; Tsaroucha A; Webb MG; Nery JR; Khan MF; Karatzas T; Khan RT; Zucker K; Viciana AL; Miller JA; Tzakis AG
    Transplant Proc; 1997 Nov; 29(7):2971-2. PubMed ID: 9365633
    [No Abstract]   [Full Text] [Related]  

  • 14. Steroid minimization in liver transplant recipients: impact on hepatitis C recurrence and post-transplant diabetes.
    Humar A; Crotteau S; Gruessner A; Kandaswamy R; Gruessner R; Payne W; Lake J
    Clin Transplant; 2007; 21(4):526-31. PubMed ID: 17645714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of mycophenolate mofetil in liver transplant recipients experiencing renal dysfunction on cyclosporine or tacrolimus-randomized, prospective, multicenter study results.
    Hodge EE; Reich DJ; Clavien PA; Kim-Schluger L
    Transplant Proc; 2002 Aug; 34(5):1546-7. PubMed ID: 12176477
    [No Abstract]   [Full Text] [Related]  

  • 16. The association between MMF and risk of progressive renal dysfunction and death in adult liver transplant recipients with HCV.
    Lake J; Patel D; David K; Richwine J; Morris J
    Clin Transplant; 2009; 23(1):108-15. PubMed ID: 19200223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mycophenolate and hepatitis C: salve on a wound or gasoline on a fire?
    Charlton MR
    Liver Transpl; 2002 Jan; 8(1):47-9. PubMed ID: 11799485
    [No Abstract]   [Full Text] [Related]  

  • 18. The role of immunosuppression in recurrence of hepatitis C.
    Lake JR
    Liver Transpl; 2003 Nov; 9(11):S63-6. PubMed ID: 14586898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of mycophenolate mofetil versus azathioprine on early recurrence of hepatitis C after liver transplantation.
    Kornberg A; Küpper B; Tannapfel A; Hommann M; Scheele J
    Int Immunopharmacol; 2005 Jan; 5(1):107-15. PubMed ID: 15589468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hot-topic debate on hepatitis C virus: the type of immunosuppression matters.
    Trotter JF
    Liver Transpl; 2011 Nov; 17 Suppl 3():S20-3. PubMed ID: 21850693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.